CAGE-B and SAGE-B models better predict the hepatitis B virus-related hepatocellular carcinoma after 5-year entecavir treatment than PAGE-B
© 2023 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd..
OBJECTIVES: The PAGE-B model consists of variables at the initiation of antiviral therapy (AVT), whereas the SAGE-B and CAGE-B models consist of variables after 5 years of AVT. We aimed to compare the predictive accuracy of three risk prediction models for hepatocellular carcinoma (HCC) development after 5 years of AVT in patients with chronic hepatitis B (CHB).
METHODS: A total of 1335 patients who initiated entecavir (ETV) treatment between 2006 and 2011 and were followed up for more than 5 years were enrolled in the study.
RESULTS: At ETV initiation, the median age was 49 years and the median score of the PAGE-B model was 14. After 5 years of ETV treatment, the median SAGE-B and CAGE-B scores were 6 and 6. During the study period, 93 (7.0%) patients developed HCC after 5-year treatment. In multivariate analysis, PAGE-B (hazard ratio [HR] 1.151, 95% confidence interval [CI] 1.087-1.219), SAGE-B (HR 1.340, 95% CI 1.228-1.463), and CAGE-B (HR 1.327, 95% CI 1.223-1.440) models independently predicted HCC development after 5 years of treatment (all P < 0.001). The high-risk groups of the three risk prediction models showed a significantly higher risk of HCC development compared to the medium- and low-risk groups (both P < 0.05). The AUROC of the SAGE-B (0.772-0.844) and CAGE-B (0.785-0.838) models was significantly higher than those of the PAGE-B model (0.696-0.745) in predicting HCC development after 5 years of treatment (both P < 0.05).
CONCLUSION: The SAGE-B and CAGE-B models might be better than the PAGE-B model in predicting HCC development after 5 years of ETV treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Journal of digestive diseases - 24(2023), 2 vom: 14. Feb., Seite 113-121 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chon, Hye Yeon [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5968Y6H45M |
|---|
| Anmerkungen: |
Date Completed 25.05.2023 Date Revised 25.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1751-2980.13172 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355618478 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355618478 | ||
| 003 | DE-627 | ||
| 005 | 20231226064726.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1751-2980.13172 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355618478 | ||
| 035 | |a (NLM)37057685 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chon, Hye Yeon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CAGE-B and SAGE-B models better predict the hepatitis B virus-related hepatocellular carcinoma after 5-year entecavir treatment than PAGE-B |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.05.2023 | ||
| 500 | |a Date Revised 25.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd. | ||
| 520 | |a OBJECTIVES: The PAGE-B model consists of variables at the initiation of antiviral therapy (AVT), whereas the SAGE-B and CAGE-B models consist of variables after 5 years of AVT. We aimed to compare the predictive accuracy of three risk prediction models for hepatocellular carcinoma (HCC) development after 5 years of AVT in patients with chronic hepatitis B (CHB) | ||
| 520 | |a METHODS: A total of 1335 patients who initiated entecavir (ETV) treatment between 2006 and 2011 and were followed up for more than 5 years were enrolled in the study | ||
| 520 | |a RESULTS: At ETV initiation, the median age was 49 years and the median score of the PAGE-B model was 14. After 5 years of ETV treatment, the median SAGE-B and CAGE-B scores were 6 and 6. During the study period, 93 (7.0%) patients developed HCC after 5-year treatment. In multivariate analysis, PAGE-B (hazard ratio [HR] 1.151, 95% confidence interval [CI] 1.087-1.219), SAGE-B (HR 1.340, 95% CI 1.228-1.463), and CAGE-B (HR 1.327, 95% CI 1.223-1.440) models independently predicted HCC development after 5 years of treatment (all P < 0.001). The high-risk groups of the three risk prediction models showed a significantly higher risk of HCC development compared to the medium- and low-risk groups (both P < 0.05). The AUROC of the SAGE-B (0.772-0.844) and CAGE-B (0.785-0.838) models was significantly higher than those of the PAGE-B model (0.696-0.745) in predicting HCC development after 5 years of treatment (both P < 0.05) | ||
| 520 | |a CONCLUSION: The SAGE-B and CAGE-B models might be better than the PAGE-B model in predicting HCC development after 5 years of ETV treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CAGE-B | |
| 650 | 4 | |a PAGE-B | |
| 650 | 4 | |a SAGE-B | |
| 650 | 4 | |a hepatitis B | |
| 650 | 4 | |a risk prediction | |
| 650 | 7 | |a entecavir |2 NLM | |
| 650 | 7 | |a 5968Y6H45M |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Lee, Han Ah |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Soo Young |e verfasserin |4 aut | |
| 700 | 1 | |a Seo, Yeon Seok |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Sang Gyune |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Chang Hun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Tae Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Ahn, Sang Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Vincent Wai-Sun |e verfasserin |4 aut | |
| 700 | 1 | |a Yip, Terry Cheuk-Fung |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Lilian Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, In Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Grace Lai-Hung |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Seung Up |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of digestive diseases |d 2007 |g 24(2023), 2 vom: 14. Feb., Seite 113-121 |w (DE-627)NLM168045079 |x 1751-2980 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:2 |g day:14 |g month:02 |g pages:113-121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1751-2980.13172 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 2 |b 14 |c 02 |h 113-121 | ||